METHYS DX

METHYS Dx is a deeptech company developing advanced non-invasive molecular diagnostic tests to monitor cancer progression in real time. Using digital PCR and proprietary DNA methylation biomarkers, its technology enables rapid, affordable, and precise tracking of tumor dynamics without requiring tissue biopsies or complex sequencing. The company’s lead assay, M-Detect* (for research use only), supports monitoring in advanced cancers, while the upcoming Onco-Me test aims to extend this capability to early-stage disease. Validated through peer-reviewed studies, METHYS Dx’s platform delivers clinically pertinent results within a day, empowering oncologists with a simple and scalable solution for improving patient management and treatment outcomes. Relevance to Patients: METHYS Dx helps clinicians monitor cancer progression in real time using innovative molecular tools for non-invasive, rapid, and highly sensitive cancer monitoring, allowing oncologists to better manage treatment and improve patient outcomes.